Despite a challenging market and poor investor sentiment, we were able to help a leading German company raise €272 million via an Accelerated Bookbuild Offering. With 12,000 employees and 35 plants worldwide and 160 years of history, Gerresheimer AG is a global partner for the pharma, biotech and cosmetic industries.
The company offers a comprehensive portfolio of pharmaceutical containment solutions, drug delivery systems and medical devices as well as solutions for the health industry. In short, the company plays an important role in improving people’s health and well-being.
Acting as Joint Global Coordinators, our team provided timely and accurate advice to Gerresheimer. By using a customised wall-crossing approach, engaging in constant dialogue with investors and with the active participation of Gerresheimer’s management and investor relations team, we were able to generate early momentum and high-quality demand. 3.14 million new shares were placed at €86.50 and delivered in April 2023.
This was the largest German primary ABB in the Healthcare sector since early 2021 – and the funds will be used by Gerresheimer to capture significant growth opportunities, with a particular focus on high value pharmaceutical containment solutions and medical devices for biologics, including GLP-1 based drugs for the treatment of obesity. This will further strengthen Gerresheimer’s leading market position.